Palisade Bio, Inc. (PALI)
NASDAQ:PALI
Want to see PALI full AI Analyst Report?
Total Valuation
Palisade Bio has a market cap or net worth of $314.18M. The enterprise value is $181.55M.
Market Cap$314.18M
Enterprise Value$181.55M
Share Statistics
Palisade Bio has 173,579,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding173,579,670
Owned by Insiders0.03%
Owned by Institutions47.36%
Financial Efficiency
Palisade Bio’s return on equity (ROE) is -0.13 and return on invested capital (ROIC) is -13.91%.
Return on Equity (ROE)-0.13
Return on Assets (ROA)-0.12
Return on Invested Capital (ROIC)-13.91%
Return on Capital Employed (ROCE)-0.14
Revenue Per Employee0.00
Profits Per Employee-2.10M
Employee Count8
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Palisade Bio is ―. Palisade Bio’s PEG ratio is 0.08.
PE Ratio―
PS Ratio0.00
PB Ratio1.01
Price to Fair Value1.01
Price to FCF-12.06
Price to Operating Cash Flow-30.59
PEG Ratio0.08
Income Statement
In the last 12 months, Palisade Bio had revenue of 0.00 and earned -16.78M in profits. Earnings per share was -0.30.
Revenue0.00
Gross Profit0.00
Operating Income-18.06M
Pretax Income-16.78M
Net Income-16.78M
EBITDA-16.77M
Earnings Per Share (EPS)-0.30
Cash Flow
In the last 12 months, operating cash flow was -12.40M and capital expenditures 0.00, giving a free cash flow of -12.40M billion.
Operating Cash Flow-12.40M
Free Cash Flow-12.40M
Free Cash Flow per Share-0.07
Dividends & Yields
Palisade Bio pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.16
52-Week Price Change144.59%
50-Day Moving Average2.00
200-Day Moving Average1.66
Relative Strength Index (RSI)42.58
Average Volume (3m)3.77M
Important Dates
Palisade Bio upcoming earnings date is Aug 25, 2026, Before Open (Confirmed).
Last Earnings DateMay 12, 2026
Next Earnings DateAug 25, 2026
Ex-Dividend Date―
Financial Position
Palisade Bio as a current ratio of 28.95, with Debt / Equity ratio of 0.00%
Current Ratio28.95
Quick Ratio28.95
Debt to Market Cap<0.01
Net Debt to EBITDA7.95
Interest Coverage Ratio-1.81K
Taxes
In the past 12 months, Palisade Bio has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Palisade Bio EV to EBITDA ratio is 0.15, with an EV/FCF ratio of 0.23.
EV to Sales0.00
EV to EBITDA0.15
EV to Free Cash Flow0.23
EV to Operating Cash Flow0.23
Balance Sheet
Palisade Bio has $132.63M in cash and marketable securities with $0.00 in debt, giving a net cash position of $132.63M billion.
Cash & Marketable Securities$132.63M
Total Debt$0.00
Net Cash$132.63M
Net Cash Per Share$0.76
Tangible Book Value Per Share$2.32
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Palisade Bio is $10.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$10.67
Price Target Upside344.44% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast―
EPS Growth Forecast88.03%